{"id":1961,"date":"2024-10-24T13:08:33","date_gmt":"2024-10-24T13:08:33","guid":{"rendered":"https:\/\/admarebio.com\/news-events\/news-insights\/"},"modified":"2026-06-26T13:08:33","modified_gmt":"2026-06-26T13:08:33","slug":"cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique","status":"publish","type":"post","link":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/","title":{"rendered":"Cancer Research UK et KisoJi Biotechnology collaborent pour faire avancer le premier anticorps nu ciblant TROP2 en clinique"},"content":{"rendered":"\n

LONDRES et MONTR\u00c9AL, 24 octobre 2024<\/strong> – Cancer Research UK, l’un des plus grands bailleurs de fonds de la recherche sur le cancer au monde, et KisoJi Biotechnology Inc., une entreprise sp\u00e9cialis\u00e9e dans la d\u00e9couverte et le d\u00e9veloppement de th\u00e9rapies \u00e0 base d’anticorps, ont sign\u00e9 un accord historique pour faire avancer l’actif principal de KisoJi, KJ-103, dans un premier essai clinique. KJ-103 est un anticorps nu anti-TROP2 d\u00e9velopp\u00e9 \u00e0 l’aide de la technologie propri\u00e9taire de KisoJi.<\/p>\n\n\n\n

Dans le cadre de cet accord, le Centre de D\u00e9veloppement de M\u00e9dicaments (CDD) de Cancer Research UK parrainera, concevra et ex\u00e9cutera un essai clinique de Phase 1\/2a de KJ-103 sur des tumeurs solides exprimant TROP2. KisoJi fournira l’anticorps pour l’essai clinique et collaborera avec le CDD pour finaliser le dossier pr\u00e9clinique. Cancer Research Horizons, la branche d’innovation de Cancer Research UK, g\u00e9rera les relations commerciales.<\/p>\n\n\n\n

Contrairement aux conjugu\u00e9s anticorps-m\u00e9dicaments (ADCs), KJ-103 n’a pas besoin de charge cytotoxique. Il agit en recrutant des cellules immunitaires pour d\u00e9truire les cellules tumorales. KJ-103 se lie \u00e0 TROP2 \u00e0 un emplacement diff\u00e9rent de celui des ADCs actuels contre TROP2 et l’utilise pour activer les macrophages, entra\u00eenant la phagocytose et la destruction des cellules tumorales exprimant cette prot\u00e9ine.<\/p>\n\n\n\n

KJ-103 pourrait offrir une alternative th\u00e9rapeutique pour les cancers exprimant TROP2, notamment dans les cas o\u00f9 les ADCs ciblant TROP2 se sont r\u00e9v\u00e9l\u00e9s inefficaces ou inadapt\u00e9s en raison de leur profil de toxicit\u00e9. Les types de tumeurs exprimant TROP2 incluent : colorectal, t\u00eate et cou, ovaire, sein, vessie et poumon.<\/p>\n\n\n\n

Lars Erwig, directeur du CDD, a exprim\u00e9 son enthousiasme pour cette collaboration, d\u00e9clarant<\/strong> : \u00ab Ce partenariat est en phase avec notre mission d’explorer des approches th\u00e9rapeutiques innovantes pour les cancers difficiles \u00e0 traiter. Avec le m\u00e9canisme d’action unique de KJ-103, qui exploite le syst\u00e8me immunitaire sans la toxicit\u00e9 potentielle d’un conjugu\u00e9, nous esp\u00e9rons offrir de nouvelles options de traitement aux patients atteints de tumeurs solides exprimant TROP2. \u00bb<\/em><\/p>\n\n\n\n

David Young, cofondateur et Directeur g\u00e9n\u00e9ral de KisoJi, a ajout\u00e9 <\/strong>: \u00ab Nous sommes ravis de faire avancer KJ-103 en clinique en partenariat avec Cancer Research UK. En tant que premier anticorps nu ciblant les cancers exprimant TROP2, KJ-103 est le premier d’une nouvelle vague d’anticorps issus de notre plateforme technologique modernis\u00e9e qui s’appuie sur l’IA, bas\u00e9e sur la biologie, pour cr\u00e9er des anticorps th\u00e9rapeutiques transformateurs. \u00bb<\/em><\/p>\n\n\n\n

\u00c0 propos du Centre de D\u00e9veloppement de M\u00e9dicaments de Cancer Research UK<\/strong><\/p>\n\n\n\n

Cancer Research UK a une longue histoire de d\u00e9veloppement de traitements innovants contre le cancer, avec 30 ans d’exp\u00e9rience dans le domaine. Le Centre de D\u00e9veloppement de M\u00e9dicaments a men\u00e9 plus de 160 agents anticanc\u00e9reux potentiels dans des essais cliniques, dont six sont arriv\u00e9s sur le march\u00e9, notamment le t\u00e9mozolomide pour le cancer du cerveau et l’abirat\u00e9rone pour le cancer de la prostate. Deux autres m\u00e9dicaments sont en Phase 3 de d\u00e9veloppement avanc\u00e9. Treize agents sont toujours en d\u00e9veloppement actif avec un potentiel d’acc\u00e8s au march\u00e9. Actuellement, le centre dispose d’un portefeuille de 16 projets en d\u00e9veloppement pr\u00e9clinique, en Phase 1 ou au d\u00e9but des essais cliniques de Phase 2.<\/p>\n\n\n\n

www.cruk.org.uk\/cdd<\/p>\n\n\n\n

\u00c0 propos de KisoJi Biotechnology<\/strong><\/p>\n\n\n\n

KisoJi Biotechnology est une entreprise canadienne sp\u00e9cialis\u00e9e dans la d\u00e9couverte d’anticorps th\u00e9rapeutiques en utilisant des outils scientifiques et d’intelligence artificielle avanc\u00e9s. KisoJi a d\u00e9velopp\u00e9 une souris transg\u00e9nique multi-esp\u00e8ces capable de g\u00e9n\u00e9rer des anticorps \u00e0 domaine unique tr\u00e8s diversifi\u00e9s, ainsi qu’une structure d’anticorps multi-sp\u00e9cifique modulaire offrant une grande stabilit\u00e9 et productivit\u00e9. Plus r\u00e9cemment, KisoJi a utilis\u00e9 des outils d’IA avanc\u00e9s pour visualiser l’univers de tous les anticorps ayant la m\u00eame cible, dans le but de d\u00e9couvrir de nouvelles biologies et de nouvelles capacit\u00e9s th\u00e9rapeutiques pour ses partenaires et pour sa propre pipeline.<\/p>\n\n\n\n

www.kisojibiotech.com<\/p>\n\n\n\n

\u00c0 propos de KJ-103<\/strong><\/p>\n\n\n\n

KJ-103 est un anticorps \u00e0 domaine unique qui se lie \u00e0 un \u00e9pitope unique de TROP2. Il agit par des m\u00e9canismes effecteurs cellulaires, notamment l’activation des macrophages pour d\u00e9truire les cellules tumorales. KJ-103 a d\u00e9montr\u00e9 une forte activit\u00e9 antitumorale sans preuve de toxicit\u00e9 ou de r\u00e9sistance dans plusieurs mod\u00e8les de tumeurs solides pr\u00e9cliniques. KJ-103 a \u00e9t\u00e9 humanis\u00e9 par LifeArc.<\/p>\n\n\n\n

Contact de Cancer Research UK:<\/strong><\/p>\n\n\n\n

Tim Bodicoat
tim.bodicoat@cancer.org.uk
+44 203 469 8300
+44 203 469 8301 (en dehors des heures de travail)<\/p>\n\n\n\n

Contact de KisoJi Biotechnology:<\/strong><\/p>\n\n\n\n

Investisseurs et M\u00e9dias
Argot Partners
Sam Martin\/Cameron
Willis KisoJi@argotpartners.com
+1 212 600 1902<\/p>\n","protected":false},"excerpt":{"rendered":"

LONDRES et MONTR\u00c9AL, 24 octobre 2024 – Cancer Research UK, l’un des plus grands bailleurs de fonds de la recherche sur le cancer au monde, et KisoJi Biotechnology Inc., une entreprise […]<\/p>\n","protected":false},"author":4,"featured_media":1945,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[41],"tags":[],"company":[116],"class_list":["post-1961","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-actualites-des-compagnies-du-portefeuille"],"yoast_head":"\nCancer Research UK et KisoJi Biotechnology collaborent pour faire avancer le premier anticorps nu ciblant TROP2 en clinique | adMare<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cancer Research UK et KisoJi Biotechnology collaborent pour faire avancer le premier anticorps nu ciblant TROP2 en clinique | adMare\" \/>\n<meta property=\"og:description\" content=\"LONDRES et MONTR\u00c9AL, 24 octobre 2024 – Cancer Research UK, l’un des plus grands bailleurs de fonds de la recherche sur le cancer au monde, et KisoJi Biotechnology Inc., une entreprise […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/\" \/>\n<meta property=\"og:site_name\" content=\"adMare\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-24T13:08:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-26T13:08:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/kisoji-news-fr-1733150499.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1198\" \/>\n\t<meta property=\"og:image:height\" content=\"628\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Earnscliffe Strategies\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Earnscliffe Strategies\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\\\/\"},\"author\":{\"name\":\"Earnscliffe Strategies\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\"},\"headline\":\"Cancer Research UK et KisoJi Biotechnology collaborent pour faire avancer le premier anticorps nu ciblant TROP2 en clinique\",\"datePublished\":\"2024-10-24T13:08:33+00:00\",\"dateModified\":\"2026-06-26T13:08:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\\\/\"},\"wordCount\":807,\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/kisoji-news-fr-1733150499.png\",\"articleSection\":[\"Actualit\u00e9s des compagnies du portefeuille\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\\\/\",\"name\":\"Cancer Research UK et KisoJi Biotechnology collaborent pour faire avancer le premier anticorps nu ciblant TROP2 en clinique | adMare\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/kisoji-news-fr-1733150499.png\",\"datePublished\":\"2024-10-24T13:08:33+00:00\",\"dateModified\":\"2026-06-26T13:08:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\\\/#primaryimage\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/kisoji-news-fr-1733150499.png\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/05\\\/kisoji-news-fr-1733150499.png\",\"width\":1198,\"height\":628},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/nouvelles-et-evenements\\\/actualites-et-perspectives\\\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News & Events\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News & Insights\",\"item\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/news-events\\\/news-insights\\\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Cancer Research UK et KisoJi Biotechnology collaborent pour faire avancer le premier anticorps nu ciblant TROP2 en clinique\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"name\":\"adMare\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#organization\",\"name\":\"adMare\",\"url\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"contentUrl\":\"https:\\\/\\\/admarebio.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/Logo-light.svg\",\"width\":915,\"height\":337,\"caption\":\"adMare\"},\"image\":{\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/admarebio.com\\\/fr\\\/#\\\/schema\\\/person\\\/bd78e975574bdbf66541602c00a312da\",\"name\":\"Earnscliffe Strategies\",\"url\":\"#\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cancer Research UK et KisoJi Biotechnology collaborent pour faire avancer le premier anticorps nu ciblant TROP2 en clinique | adMare","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"fr_FR","og_type":"article","og_title":"Cancer Research UK et KisoJi Biotechnology collaborent pour faire avancer le premier anticorps nu ciblant TROP2 en clinique | adMare","og_description":"LONDRES et MONTR\u00c9AL, 24 octobre 2024 – Cancer Research UK, l’un des plus grands bailleurs de fonds de la recherche sur le cancer au monde, et KisoJi Biotechnology Inc., une entreprise […]","og_url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/","og_site_name":"adMare","article_published_time":"2024-10-24T13:08:33+00:00","article_modified_time":"2026-06-26T13:08:33+00:00","og_image":[{"width":1198,"height":628,"url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/kisoji-news-fr-1733150499.png","type":"image\/png"}],"author":"Earnscliffe Strategies","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Earnscliffe Strategies","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/#article","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/"},"author":{"name":"Earnscliffe Strategies","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da"},"headline":"Cancer Research UK et KisoJi Biotechnology collaborent pour faire avancer le premier anticorps nu ciblant TROP2 en clinique","datePublished":"2024-10-24T13:08:33+00:00","dateModified":"2026-06-26T13:08:33+00:00","mainEntityOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/"},"wordCount":807,"publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/kisoji-news-fr-1733150499.png","articleSection":["Actualit\u00e9s des compagnies du portefeuille"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/","url":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/","name":"Cancer Research UK et KisoJi Biotechnology collaborent pour faire avancer le premier anticorps nu ciblant TROP2 en clinique | adMare","isPartOf":{"@id":"https:\/\/admarebio.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/#primaryimage"},"image":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/#primaryimage"},"thumbnailUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/kisoji-news-fr-1733150499.png","datePublished":"2024-10-24T13:08:33+00:00","dateModified":"2026-06-26T13:08:33+00:00","breadcrumb":{"@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/#primaryimage","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/kisoji-news-fr-1733150499.png","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/05\/kisoji-news-fr-1733150499.png","width":1198,"height":628},{"@type":"BreadcrumbList","@id":"https:\/\/admarebio.com\/fr\/nouvelles-et-evenements\/actualites-et-perspectives\/cancer-research-uk-et-kisoji-biotechnology-collaborent-pour-faire-avancer-le-premier-anticorps-nu-ciblant-trop2-en-clinique\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/admarebio.com\/fr\/"},{"@type":"ListItem","position":2,"name":"News & Events","item":"https:\/\/admarebio.com\/fr\/news-events\/"},{"@type":"ListItem","position":3,"name":"News & Insights","item":"https:\/\/admarebio.com\/fr\/news-events\/news-insights\/"},{"@type":"ListItem","position":4,"name":"Cancer Research UK et KisoJi Biotechnology collaborent pour faire avancer le premier anticorps nu ciblant TROP2 en clinique"}]},{"@type":"WebSite","@id":"https:\/\/admarebio.com\/fr\/#website","url":"https:\/\/admarebio.com\/fr\/","name":"adMare","description":"","publisher":{"@id":"https:\/\/admarebio.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/admarebio.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/admarebio.com\/fr\/#organization","name":"adMare","url":"https:\/\/admarebio.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","contentUrl":"https:\/\/admarebio.com\/wp-content\/uploads\/2026\/03\/Logo-light.svg","width":915,"height":337,"caption":"adMare"},"image":{"@id":"https:\/\/admarebio.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/admarebio.com\/fr\/#\/schema\/person\/bd78e975574bdbf66541602c00a312da","name":"Earnscliffe Strategies","url":"#"}]}},"_links":{"self":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/comments?post=1961"}],"version-history":[{"count":1,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1961\/revisions"}],"predecessor-version":[{"id":1962,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/posts\/1961\/revisions\/1962"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media\/1945"}],"wp:attachment":[{"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/media?parent=1961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/categories?post=1961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/tags?post=1961"},{"taxonomy":"company","embeddable":true,"href":"https:\/\/admarebio.com\/fr\/wp-json\/wp\/v2\/company?post=1961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}